<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01512251</url>
  </required_header>
  <id_info>
    <org_study_id>11952</org_study_id>
    <secondary_id>CBKM120ZUS21T</secondary_id>
    <nct_id>NCT01512251</nct_id>
  </id_info>
  <brief_title>BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma</brief_title>
  <official_title>A Phase 1/2 Trial of BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma (Novartis Study Number CBKM120ZUS21T)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1/2 clinical trial with the goal of determining whether the addition of the
      investigational agent BKM120 to vemurafenib will lead to improved 6-month progression-free
      survival in patients with BRAFV600E/K mutant melanoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The phase 1 portion of this trial is a dose escalation study; the phase 2 portion is a
      single-stage, single arm prospective clinical trial. All patients will receive continuous
      doses of vemurafenib twice a day and BKM120 once a day.

      In the phase 1 portion of the study, there will be a 7 day lead-in period to allow for single
      dose pharmacokinetic analysis of BKM120 alone. Cycle 1 (28 days) is the dose-limiting
      toxicity (DLT) period. During phase 1, vemurafenib and BKM120 doses will be escalated using a
      standard 3+3 dose escalation scheme with the goal of identifying the recommended phase 2
      dose.

      In the phase 2 portion of the study, patients will receive continuous doses of vemurafenib
      and BKM120 starting on day 1 of the first cycle. In the phase 2 portion of the study,
      patients will receive vemurafenib and BKM120 at the recommended phase 2 dose.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 9, 2012</start_date>
  <completion_date type="Actual">March 21, 2017</completion_date>
  <primary_completion_date type="Actual">December 13, 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1 - Safety &amp; Recommended Phase 2 Dose (RP2D)</measure>
    <time_frame>28 days</time_frame>
    <description>RP2D determined by MTD, post-DLT period toxicity, and pharmacokinetic data</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2 - Progression-free Survival Rate</measure>
    <time_frame>6 months</time_frame>
    <description>6 month progression-free survival rate (PFS6) determined by tumor assessments, clinical tests and laboratory tests</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcome 1 Phase 2 - Objective Response Rate</measure>
    <time_frame>Day 28 (+/- 3) of even-numbered treatment cycles until progression</time_frame>
    <description>Objective response rate determined by tumor assessments, clinical tests and laboratory tests.
Data not collected: study was terminated early due to dose limiting toxicities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcome 2 Phase 2 - Safety and Tolerability</measure>
    <time_frame>During study treatment, up to 2 years</time_frame>
    <description>Determined by clinical and laboratory tests, and AE assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcome 3 Phase 2 - PTEN Expression</measure>
    <time_frame>No time limit</time_frame>
    <description>PTEN expression associated with better PFS determined by laboratory tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcome 4 Phase 2 - PI3K-pathway Signaling Reduction Levels</measure>
    <time_frame>No time limit</time_frame>
    <description>Greater reduction in PI3K-pathway signaling associated with better PFS determined by laboratory tests and tumor assessments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcome 5 Phase 2 - PI3K Pathway Gene Expression Levels</measure>
    <time_frame>No time limit</time_frame>
    <description>Responding tumors lack gene expression signatures of PI3K pathway activation, and progressing tumors demonstrate gene expression signatures of PI3K pathway activation - determined by laboratory tests and tumor assessments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcome 6 Phase 2 - MAPK Pathway Gene Expression Levels</measure>
    <time_frame>No time limit</time_frame>
    <description>Responding tumors lack gene expression signatures of MAPK pathway activation, and progressing tumors demonstrate gene expression signatures of MAPK pathway activation - determined by laboratory tests and tumor assessments.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>BRAF Mutant Metastatic Melanoma</condition>
  <arm_group>
    <arm_group_label>No Previous Treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>150 mg oral dabrafenib twice a day until disease progression, death, or unacceptable adverse events.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BKM120 Combined with Vemurafenib (PLX4032)</intervention_name>
    <description>Phase I is 3+3 dose escalation study to identify the recommended phase 2 dose (RP2D)
Dose Level -1: BKM120 60 mg daily, Vemurafenib 480 mg bid
Dose Level 1: BKM120 60 mg daily, Vemurafenib 720 mg bid
Dose Level 2: BKM120 80 mg daiy, Vemurafenib 720 mg bid
Dose Level 3: BKM120 100 mg daiy, Vemurafenib 720 mg bid
Dose Level 4: BKM120 100 mg daiy, Vemurafenib 960 mg bid
Phase II is a single-stage, single arm prospective trial: patients will receive BKM120 and vemurafenib at the RP2D</description>
    <arm_group_label>No Previous Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Histologically or cytologically confirmed diagnosis of unresectable stage III and
             stage IV melanoma

          2. BRAFV600E or BRAFV600K mutation-positive

          3. Age ≥ 18 years

          4. ECOG performance status ≤ 2

          5. Patients must have at least one site of measurable disease (per RECIST for solid
             tumors)

          6. Life expectancy of ≥ 12 weeks

          7. Adequate bone marrow function as shown by: ANC ≥ 1.5 x 109/L, Platelets ≥ 100 x 109/L,
             Hb &gt;9 g/dL

          8. Total calcium (corrected for serum albumin) within normal limits (biphosphonate use
             for malignant hypercalcemia control is not allowed)

          9. Magnesium ≥ the lower limit of normal

         10. Potassium within normal limits for the institution

         11. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) within normal
             range (or ≤ 3.0 x upper limit of normal (ULN) if liver metastases are present)

         12. Serum bilirubin within normal range (or ≤ 1.5 x ULN if liver metastases are present;
             or total bilirubin ≤ 3.0 x ULN with direct bilirubin within normal range in patients
             with well documented Gilbert Syndrome)

         13. Serum creatinine ≤ 1.5 x ULN or 24-hour clearance ≥ 50 mL/min

         14. Serum amylase ≤ ULN

         15. Serum lipase ≤ ULN

         16. INR ≤ 2

         17. Fasting plasma glucose ≤ 120 mg/dL (6.7 mmol/L)

         18. Negative serum pregnancy test within 48 hours before starting study treatment

        Exclusion Criteria

          1. Patients who have received prior treatment with a PI3K inhibitor or a BRAF inhibitor,
             prior treatment with sorafenib is permitted.

          2. Patients with a known hypersensitivity to BKM120 or to its excipients

          3. Patients with untreated brain metastases are excluded; however, patients with
             metastatic CNS tumors may participate in this trial, if the patient is &gt; 4 weeks from
             therapy completion (incl. radiation and/or surgery) and clinically stable at the time
             of study entry

          4. Patients with acute or chronic liver, renal disease or pancreatitis

          5. Patients with the following mood disorders as judged by the Investigator or a
             psychiatrist, or as a result of patient's mood assessment questionnaire:

               -  Medically documented history of or active major depressive episode, bipolar
                  disorder (I or II), obsessive-compulsive disorder, schizophrenia, history of
                  suicidal attempt or ideation, or homicidal ideation

               -  ≥ CTCAE grade 3 anxiety

               -  Meets the cut-off score of ≥ 10 in the PHQ-9 or a cut-off of ≥ 15 in the GAD-7
                  mood scale, respectively, or selects a positive response of &quot;1, 2, or 3&quot; to
                  question number 9 regarding potential for suicidal thoughts in the PHQ-9
                  (independent of the total score of the PHQ-9) will be excluded from the study
                  unless overruled by the psychiatric assessment

          6. Patients with diarrhea ≥ CTCAE grade 2

          7. Patient has active cardiac disease including any of the following:

               -  Left ventricular ejection fraction (LVEF) &lt; 50% as determined by MUGA or ECHO

               -  QTc &gt; 480 msec on screening ECG (using the QTcF formula)

               -  Personal or family history of prolonged QT syndrome

               -  Angina pectoris that requires the use of anti-anginal medication

               -  Ventricular arrhythmias except for benign premature ventricular contractions

               -  Supraventricular and nodal arrythmias requiring a pacemaker or not controlled
                  with medication

               -  Conduction abnormality requiring a pacemaker

               -  Symptomatic pericarditis

          8. Patient has a history of cardiac dysfunction including any of the following:

               -  Myocardial infarction within the last 6 months, documented by persistent elevated
                  cardiac enzymes or persistent regional wall abnormalities on assessment of LVEF
                  function

               -  History of documented congestive heart failure (New York Heart Association
                  functional classification III-IV)

               -  Documented cardiomyopathy

          9. Poorly controlled diabetes mellitus (HbA1c &gt; 8 %)

         10. Other concurrent severe and/or uncontrolled concomitant medical conditions that could
             cause unacceptable safety risks or compromise compliance with the protocol

             - Significant symptomatic deterioration of lung function; if clinically indicated,
             pulmonary function tests including measures of predicted lung volumes, DLco, O2
             saturation at rest on room air should be considered to exclude pneumonitis or
             pulmonary infiltrates

         11. Impairment of GI function or GI disease that may significantly alter the absorption of
             BKM120 (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea,
             malabsorption syndrome, or small bowel resection)

         12. Patients who have been treated with any hematopoietic colony-stimulating growth
             factors (e.g., G-CSF, GM-CSF) ≤ 2 weeks prior to starting study drug; erythropoietin
             or darbepoetin therapy, if initiated at least 2 weeks prior to enrollment, may be
             continued

         13. Patients who are currently receiving treatment with medication with a known risk to
             prolong the QT interval or inducing Torsades de Pointes and the treatment cannot
             either be discontinued or switched to a different medication prior to starting study
             drug

         14. Patients receiving chronic treatment with steroids or another immunosuppressive agent;
             topical applications, inhaled sprays, eye drops or local injections are allowed;
             patients with previously treated brain metastases, who are on stable low dose
             corticosteroids treatment for at least 14 days before start of study treatment are
             eligible

         15. Patients who have taken herbal medications and certain fruits within 7 days prior to
             starting study drug - herbal medications include, but are not limited to St. John's
             Wort, Kava, ephedra (ma huang), gingko biloba, DHEA, yohimbe, saw palmetto, and
             ginseng; fruits include CYP3A inhibitors: Seville oranges, grapefruit, pomelos, or
             exotic citrus fruits

         16. Patients who are currently treated with drugs known to be moderate and strong
             inhibitors or inducers of isoenzyme CYP3A, and the treatment cannot be discontinued or
             switched to a different medication prior to starting study drug; note that
             co-treatment with weak inhibitors of CYP3A is allowed).

         17. Patients who have received chemotherapy or targeted anticancer therapy ≤ 4 weeks (6
             weeks for nitrosourea, antibodies or mitomycin-C) prior to starting study drug must
             have resolution of treatment related adverse events to baseline or grade 1 before
             starting the trial

         18. Patients who have received wide field radiotherapy ≤ 4 weeks or limited field
             radiation for palliation ≤ 2 weeks prior to starting study drug or who have not
             recovered from side effects of such therapy

         19. Patients who have undergone major surgery ≤ 2 weeks prior to starting study drug or
             who have not recovered from side effects of such therapy

         20. Patients who are currently taking therapeutic doses of warfarin sodium or any other
             coumadin-derivative anticoagulant

         21. Women who are pregnant or breast feeding or adults of reproductive potential not
             employing an effective method of birth control; women of child-bearing potential must
             have a negative serum pregnancy test ≤ 72 hours prior to initiating treatment; double
             barrier contraceptives must be used through the trial by both sexes; oral,
             implantable, or injectable contraceptives are therefore not considered effective for
             this study

               -  Women are considered post-menopausal and not of child bearing potential if they
                  have had 12 months of natural (spontaneous) amenorrhea with an appropriate
                  clinical profile (e.g. age appropriate, history of vasomotor symptoms) or six
                  months of spontaneous amenorrhea with serum FSH levels &gt; 40 mIU/mL [for US only:
                  and estradiol &lt; 20 pg/mL] or have had surgical bilateral oophorectomy (with or
                  without hysterectomy) at least six weeks ago. In the case of oophorectomy alone,
                  only when the reproductive status of the woman has been confirmed by follow up
                  hormone level assessment is she considered not of child bearing potential.

               -  Women of child-bearing potential, defined as all women physiologically capable of
                  becoming pregnant, must use highly effective contraception during treatment for 3
                  months in total after study drug discontinuation. Highly effective contraception
                  is defined as either: True abstinence-when this is in line with the preferred and
                  usual lifestyle of the subject, periodic abstinence and withdrawal are not
                  acceptable methods of contraception; Sterilization-have had surgical bilateral
                  oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks
                  ago; Male partner sterilization-for female subjects, the vasectomised male
                  partner should be the sole partner for that patient; Use of a combination of any
                  two of the following barrier methods of contraception-condom or Occlusive cap
                  with spermicidal foam/gel/film/cream/vaginal suppository

               -  Fertile males, defined as all males physiologically capable of conceiving
                  offspring must use condom during treatment, for 3 months in total after study
                  drug discontinuation and should not father a child in this period

         22. Known diagnosis of human immunodeficiency virus (HIV) infection

         23. History of another malignancy within 3 years, except cured or curable basal cell
             carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ of
             the cervix; patients with lesions curable by excision must have these lesions excised
             prior to the initiation of treatment on study

         24. Patient is unable or unwilling to abide by the study protocol or cooperate fully with
             the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2011</study_first_submitted>
  <study_first_submitted_qc>January 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2012</study_first_posted>
  <results_first_submitted>February 23, 2018</results_first_submitted>
  <results_first_submitted_qc>April 16, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">May 16, 2018</results_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Alain Algazi</investigator_full_name>
    <investigator_title>Assistant Clinical Professor - Melanoma Oncology</investigator_title>
  </responsible_party>
  <keyword>BKM120</keyword>
  <keyword>BRAF</keyword>
  <keyword>Melanoma</keyword>
  <keyword>PI3K</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vemurafenib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Vemurafenib-Naïve</title>
          <description>150 mg oral dabrafenib twice a day (bid) until disease progression, death, or unacceptable adverse events.
Dose Level -1:
BKM120 60 mg daily Vemurafenib 480 mg bid
Phase I, Dose Level 1:
BKM120 60 mg daily Vemurafenib 720 mg bid
Phase I, Dose Level 2:
BKM120 80 mg daily Vemurafenib 720 mg bid
Phase I, Dose Level 3:
BKM120 100 mg daily Vemurafenib 720 mg bid
Phase I, Dose Level 4 BKM120 100 mg daily Vemurafenib 960 mg bid
Phase II 150 mg oral dabrafenib twice a day (bid) until disease progression, death, or unacceptable adverse events.
BKM120 Combined with Vemurafenib (PLX4032): Phase I is 3+3 dose escalation study to identify the recommended phase 2 dose (RP2D)</description>
        </group>
        <group group_id="P2">
          <title>Vemurafenib-Resistant</title>
          <description>150 mg oral dabrafenib twice a day (bid) until disease progression, death, or unacceptable adverse events.
Dose Level -1:
BKM120 60 mg daily Vemurafenib 480 mg bid
Phase I, Dose Level 1:
BKM120 60 mg daily Vemurafenib 720 mg bid
Phase I, Dose Level 2:
BKM120 80 mg daily Vemurafenib 720 mg bid
Phase I, Dose Level 3:
BKM120 100 mg daily Vemurafenib 720 mg bid
Phase I, Dose Level 4 BKM120 100 mg daily Vemurafenib 960 mg bid
Phase II 150 mg oral dabrafenib twice a day (bid) until disease progression, death, or unacceptable adverse events.
BKM120 Combined with Vemurafenib (PLX4032): Phase I is 3+3 dose escalation study to identify the recommended phase 2 dose (RP2D)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Dose Level -1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Phase I, Dose 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Phase I, Dose 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Phase I, Dose 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Phase I, Dose 4</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Phase II</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vemurafenib-Naïve</title>
        </group>
        <group group_id="B2">
          <title>Vemurafenib-Resistant</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44" lower_limit="26" upper_limit="75"/>
                    <measurement group_id="B2" value="51" lower_limit="40" upper_limit="62"/>
                    <measurement group_id="B3" value="50" lower_limit="26" upper_limit="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Phase 1 - Safety &amp; Recommended Phase 2 Dose (RP2D)</title>
        <description>RP2D determined by MTD, post-DLT period toxicity, and pharmacokinetic data</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Determination of MTD</title>
            <description>Vemurafenib-Naïve and Vemurafenib-Resistant populations received:
150 mg oral dabrafenib twice a day (bid) until disease progression, death, or unacceptable adverse events.
Dose Level -1:
BKM120 60 mg daily Vemurafenib 480 mg bid
Phase I, Dose Level 1:
BKM120 60 mg daily Vemurafenib 720 mg bid</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1 - Safety &amp; Recommended Phase 2 Dose (RP2D)</title>
          <description>RP2D determined by MTD, post-DLT period toxicity, and pharmacokinetic data</description>
          <units>mg</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Phase 2 - Progression-free Survival Rate</title>
        <description>6 month progression-free survival rate (PFS6) determined by tumor assessments, clinical tests and laboratory tests</description>
        <time_frame>6 months</time_frame>
        <population>Data were not collected, study never advanced to Phase II.</population>
        <group_list>
          <group group_id="O1">
            <title>Vemurafenib-Naïve</title>
            <description>150 mg oral dabrafenib twice a day (bid) until disease progression, death, or unacceptable adverse events.
Dose Level -1:
BKM120 60 mg daily Vemurafenib 480 mg bid
Phase I, Dose Level 1:
BKM120 60 mg daily Vemurafenib 720 mg bid
Phase I, Dose Level 2:
BKM120 80 mg daily Vemurafenib 720 mg bid
Phase I, Dose Level 3:
BKM120 100 mg daily Vemurafenib 720 mg bid
Phase I, Dose Level 4 BKM120 100 mg daily Vemurafenib 960 mg bid
Phase II 150 mg oral dabrafenib twice a day (bid) until disease progression, death, or unacceptable adverse events.
BKM120 Combined with Vemurafenib (PLX4032): Phase I is 3+3 dose escalation study to identify the recommended phase 2 dose (RP2D)</description>
          </group>
          <group group_id="O2">
            <title>Vemurafenib-Resistant</title>
            <description>150 mg oral dabrafenib twice a day (bid) until disease progression, death, or unacceptable adverse events.
Dose Level -1:
BKM120 60 mg daily Vemurafenib 480 mg bid
Phase I, Dose Level 1:
BKM120 60 mg daily Vemurafenib 720 mg bid
Phase I, Dose Level 2:
BKM120 80 mg daily Vemurafenib 720 mg bid
Phase I, Dose Level 3:
BKM120 100 mg daily Vemurafenib 720 mg bid
Phase I, Dose Level 4 BKM120 100 mg daily Vemurafenib 960 mg bid
Phase II 150 mg oral dabrafenib twice a day (bid) until disease progression, death, or unacceptable adverse events.
BKM120 Combined with Vemurafenib (PLX4032): Phase I is 3+3 dose escalation study to identify the recommended phase 2 dose (RP2D)</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2 - Progression-free Survival Rate</title>
          <description>6 month progression-free survival rate (PFS6) determined by tumor assessments, clinical tests and laboratory tests</description>
          <population>Data were not collected, study never advanced to Phase II.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Outcome 1 Phase 2 - Objective Response Rate</title>
        <description>Objective response rate determined by tumor assessments, clinical tests and laboratory tests.
Data not collected: study was terminated early due to dose limiting toxicities.</description>
        <time_frame>Day 28 (+/- 3) of even-numbered treatment cycles until progression</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vemurafenib-Naïve</title>
            <description>150 mg oral dabrafenib twice a day (bid) until disease progression, death, or unacceptable adverse events.
Dose Level -1:
BKM120 60 mg daily Vemurafenib 480 mg bid
Phase I, Dose Level 1:
BKM120 60 mg daily Vemurafenib 720 mg bid
Phase I, Dose Level 2:
BKM120 80 mg daily Vemurafenib 720 mg bid
Phase I, Dose Level 3:
BKM120 100 mg daily Vemurafenib 720 mg bid
Phase I, Dose Level 4 BKM120 100 mg daily Vemurafenib 960 mg bid
Phase II 150 mg oral dabrafenib twice a day (bid) until disease progression, death, or unacceptable adverse events.
BKM120 Combined with Vemurafenib (PLX4032): Phase I is 3+3 dose escalation study to identify the recommended phase 2 dose (RP2D)</description>
          </group>
          <group group_id="O2">
            <title>Vemurafenib-Resistant</title>
            <description>150 mg oral dabrafenib twice a day (bid) until disease progression, death, or unacceptable adverse events.
Dose Level -1:
BKM120 60 mg daily Vemurafenib 480 mg bid
Phase I, Dose Level 1:
BKM120 60 mg daily Vemurafenib 720 mg bid
Phase I, Dose Level 2:
BKM120 80 mg daily Vemurafenib 720 mg bid
Phase I, Dose Level 3:
BKM120 100 mg daily Vemurafenib 720 mg bid
Phase I, Dose Level 4 BKM120 100 mg daily Vemurafenib 960 mg bid
Phase II 150 mg oral dabrafenib twice a day (bid) until disease progression, death, or unacceptable adverse events.
BKM120 Combined with Vemurafenib (PLX4032): Phase I is 3+3 dose escalation study to identify the recommended phase 2 dose (RP2D)</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary Outcome 1 Phase 2 - Objective Response Rate</title>
          <description>Objective response rate determined by tumor assessments, clinical tests and laboratory tests.
Data not collected: study was terminated early due to dose limiting toxicities.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Outcome 2 Phase 2 - Safety and Tolerability</title>
        <description>Determined by clinical and laboratory tests, and AE assessments</description>
        <time_frame>During study treatment, up to 2 years</time_frame>
        <population>Data not collected: study was terminated early due to dose limiting toxicities.</population>
        <group_list>
          <group group_id="O1">
            <title>Vemurafenib-Naïve</title>
            <description>150 mg oral dabrafenib twice a day (bid) until disease progression, death, or unacceptable adverse events.
Dose Level -1:
BKM120 60 mg daily Vemurafenib 480 mg bid
Phase I, Dose Level 1:
BKM120 60 mg daily Vemurafenib 720 mg bid
Phase I, Dose Level 2:
BKM120 80 mg daily Vemurafenib 720 mg bid
Phase I, Dose Level 3:
BKM120 100 mg daily Vemurafenib 720 mg bid
Phase I, Dose Level 4 BKM120 100 mg daily Vemurafenib 960 mg bid
Phase II 150 mg oral dabrafenib twice a day (bid) until disease progression, death, or unacceptable adverse events.
BKM120 Combined with Vemurafenib (PLX4032): Phase I is 3+3 dose escalation study to identify the recommended phase 2 dose (RP2D)</description>
          </group>
          <group group_id="O2">
            <title>Vemurafenib-Resistant</title>
            <description>150 mg oral dabrafenib twice a day (bid) until disease progression, death, or unacceptable adverse events.
Dose Level -1:
BKM120 60 mg daily Vemurafenib 480 mg bid
Phase I, Dose Level 1:
BKM120 60 mg daily Vemurafenib 720 mg bid
Phase I, Dose Level 2:
BKM120 80 mg daily Vemurafenib 720 mg bid
Phase I, Dose Level 3:
BKM120 100 mg daily Vemurafenib 720 mg bid
Phase I, Dose Level 4 BKM120 100 mg daily Vemurafenib 960 mg bid
Phase II 150 mg oral dabrafenib twice a day (bid) until disease progression, death, or unacceptable adverse events.
BKM120 Combined with Vemurafenib (PLX4032): Phase I is 3+3 dose escalation study to identify the recommended phase 2 dose (RP2D)</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary Outcome 2 Phase 2 - Safety and Tolerability</title>
          <description>Determined by clinical and laboratory tests, and AE assessments</description>
          <population>Data not collected: study was terminated early due to dose limiting toxicities.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Outcome 3 Phase 2 - PTEN Expression</title>
        <description>PTEN expression associated with better PFS determined by laboratory tests.</description>
        <time_frame>No time limit</time_frame>
        <population>Data not collected: study was terminated early due to dose limiting toxicities.</population>
        <group_list>
          <group group_id="O1">
            <title>Vemurafenib-Naïve</title>
            <description>150 mg oral dabrafenib twice a day (bid) until disease progression, death, or unacceptable adverse events.
Dose Level -1:
BKM120 60 mg daily Vemurafenib 480 mg bid
Phase I, Dose Level 1:
BKM120 60 mg daily Vemurafenib 720 mg bid
Phase I, Dose Level 2:
BKM120 80 mg daily Vemurafenib 720 mg bid
Phase I, Dose Level 3:
BKM120 100 mg daily Vemurafenib 720 mg bid
Phase I, Dose Level 4 BKM120 100 mg daily Vemurafenib 960 mg bid
Phase II 150 mg oral dabrafenib twice a day (bid) until disease progression, death, or unacceptable adverse events.
BKM120 Combined with Vemurafenib (PLX4032): Phase I is 3+3 dose escalation study to identify the recommended phase 2 dose (RP2D)</description>
          </group>
          <group group_id="O2">
            <title>Vemurafenib-Resistant</title>
            <description>150 mg oral dabrafenib twice a day (bid) until disease progression, death, or unacceptable adverse events.
Dose Level -1:
BKM120 60 mg daily Vemurafenib 480 mg bid
Phase I, Dose Level 1:
BKM120 60 mg daily Vemurafenib 720 mg bid
Phase I, Dose Level 2:
BKM120 80 mg daily Vemurafenib 720 mg bid
Phase I, Dose Level 3:
BKM120 100 mg daily Vemurafenib 720 mg bid
Phase I, Dose Level 4 BKM120 100 mg daily Vemurafenib 960 mg bid
Phase II 150 mg oral dabrafenib twice a day (bid) until disease progression, death, or unacceptable adverse events.
BKM120 Combined with Vemurafenib (PLX4032): Phase I is 3+3 dose escalation study to identify the recommended phase 2 dose (RP2D)</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary Outcome 3 Phase 2 - PTEN Expression</title>
          <description>PTEN expression associated with better PFS determined by laboratory tests.</description>
          <population>Data not collected: study was terminated early due to dose limiting toxicities.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Outcome 4 Phase 2 - PI3K-pathway Signaling Reduction Levels</title>
        <description>Greater reduction in PI3K-pathway signaling associated with better PFS determined by laboratory tests and tumor assessments.</description>
        <time_frame>No time limit</time_frame>
        <population>Data not collected: study was terminated early due to dose limiting toxicities.</population>
        <group_list>
          <group group_id="O1">
            <title>Vemurafenib-Naïve</title>
            <description>150 mg oral dabrafenib twice a day (bid) until disease progression, death, or unacceptable adverse events.
Dose Level -1:
BKM120 60 mg daily Vemurafenib 480 mg bid
Phase I, Dose Level 1:
BKM120 60 mg daily Vemurafenib 720 mg bid
Phase I, Dose Level 2:
BKM120 80 mg daily Vemurafenib 720 mg bid
Phase I, Dose Level 3:
BKM120 100 mg daily Vemurafenib 720 mg bid
Phase I, Dose Level 4 BKM120 100 mg daily Vemurafenib 960 mg bid
Phase II 150 mg oral dabrafenib twice a day (bid) until disease progression, death, or unacceptable adverse events.
BKM120 Combined with Vemurafenib (PLX4032): Phase I is 3+3 dose escalation study to identify the recommended phase 2 dose (RP2D)</description>
          </group>
          <group group_id="O2">
            <title>Vemurafenib-Resistant</title>
            <description>150 mg oral dabrafenib twice a day (bid) until disease progression, death, or unacceptable adverse events.
Dose Level -1:
BKM120 60 mg daily Vemurafenib 480 mg bid
Phase I, Dose Level 1:
BKM120 60 mg daily Vemurafenib 720 mg bid
Phase I, Dose Level 2:
BKM120 80 mg daily Vemurafenib 720 mg bid
Phase I, Dose Level 3:
BKM120 100 mg daily Vemurafenib 720 mg bid
Phase I, Dose Level 4 BKM120 100 mg daily Vemurafenib 960 mg bid
Phase II 150 mg oral dabrafenib twice a day (bid) until disease progression, death, or unacceptable adverse events.
BKM120 Combined with Vemurafenib (PLX4032): Phase I is 3+3 dose escalation study to identify the recommended phase 2 dose (RP2D)</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary Outcome 4 Phase 2 - PI3K-pathway Signaling Reduction Levels</title>
          <description>Greater reduction in PI3K-pathway signaling associated with better PFS determined by laboratory tests and tumor assessments.</description>
          <population>Data not collected: study was terminated early due to dose limiting toxicities.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Outcome 5 Phase 2 - PI3K Pathway Gene Expression Levels</title>
        <description>Responding tumors lack gene expression signatures of PI3K pathway activation, and progressing tumors demonstrate gene expression signatures of PI3K pathway activation - determined by laboratory tests and tumor assessments.</description>
        <time_frame>No time limit</time_frame>
        <population>Data not collected: study was terminated early due to dose limiting toxicities.</population>
        <group_list>
          <group group_id="O1">
            <title>Vemurafenib-Naïve</title>
            <description>150 mg oral dabrafenib twice a day (bid) until disease progression, death, or unacceptable adverse events.
Dose Level -1:
BKM120 60 mg daily Vemurafenib 480 mg bid
Phase I, Dose Level 1:
BKM120 60 mg daily Vemurafenib 720 mg bid
Phase I, Dose Level 2:
BKM120 80 mg daily Vemurafenib 720 mg bid
Phase I, Dose Level 3:
BKM120 100 mg daily Vemurafenib 720 mg bid
Phase I, Dose Level 4 BKM120 100 mg daily Vemurafenib 960 mg bid
Phase II 150 mg oral dabrafenib twice a day (bid) until disease progression, death, or unacceptable adverse events.
BKM120 Combined with Vemurafenib (PLX4032): Phase I is 3+3 dose escalation study to identify the recommended phase 2 dose (RP2D)</description>
          </group>
          <group group_id="O2">
            <title>Vemurafenib-Resistant</title>
            <description>150 mg oral dabrafenib twice a day (bid) until disease progression, death, or unacceptable adverse events.
Dose Level -1:
BKM120 60 mg daily Vemurafenib 480 mg bid
Phase I, Dose Level 1:
BKM120 60 mg daily Vemurafenib 720 mg bid
Phase I, Dose Level 2:
BKM120 80 mg daily Vemurafenib 720 mg bid
Phase I, Dose Level 3:
BKM120 100 mg daily Vemurafenib 720 mg bid
Phase I, Dose Level 4 BKM120 100 mg daily Vemurafenib 960 mg bid
Phase II 150 mg oral dabrafenib twice a day (bid) until disease progression, death, or unacceptable adverse events.
BKM120 Combined with Vemurafenib (PLX4032): Phase I is 3+3 dose escalation study to identify the recommended phase 2 dose (RP2D)</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary Outcome 5 Phase 2 - PI3K Pathway Gene Expression Levels</title>
          <description>Responding tumors lack gene expression signatures of PI3K pathway activation, and progressing tumors demonstrate gene expression signatures of PI3K pathway activation - determined by laboratory tests and tumor assessments.</description>
          <population>Data not collected: study was terminated early due to dose limiting toxicities.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Outcome 6 Phase 2 - MAPK Pathway Gene Expression Levels</title>
        <description>Responding tumors lack gene expression signatures of MAPK pathway activation, and progressing tumors demonstrate gene expression signatures of MAPK pathway activation - determined by laboratory tests and tumor assessments.</description>
        <time_frame>No time limit</time_frame>
        <population>Data not collected: study was terminated early due to dose limiting toxicities.</population>
        <group_list>
          <group group_id="O1">
            <title>Vemurafenib-Naïve</title>
            <description>150 mg oral dabrafenib twice a day (bid) until disease progression, death, or unacceptable adverse events.
Dose Level -1:
BKM120 60 mg daily Vemurafenib 480 mg bid
Phase I, Dose Level 1:
BKM120 60 mg daily Vemurafenib 720 mg bid
Phase I, Dose Level 2:
BKM120 80 mg daily Vemurafenib 720 mg bid
Phase I, Dose Level 3:
BKM120 100 mg daily Vemurafenib 720 mg bid
Phase I, Dose Level 4 BKM120 100 mg daily Vemurafenib 960 mg bid
Phase II 150 mg oral dabrafenib twice a day (bid) until disease progression, death, or unacceptable adverse events.
BKM120 Combined with Vemurafenib (PLX4032): Phase I is 3+3 dose escalation study to identify the recommended phase 2 dose (RP2D)</description>
          </group>
          <group group_id="O2">
            <title>Vemurafenib-Resistant</title>
            <description>150 mg oral dabrafenib twice a day (bid) until disease progression, death, or unacceptable adverse events.
Dose Level -1:
BKM120 60 mg daily Vemurafenib 480 mg bid
Phase I, Dose Level 1:
BKM120 60 mg daily Vemurafenib 720 mg bid
Phase I, Dose Level 2:
BKM120 80 mg daily Vemurafenib 720 mg bid
Phase I, Dose Level 3:
BKM120 100 mg daily Vemurafenib 720 mg bid
Phase I, Dose Level 4 BKM120 100 mg daily Vemurafenib 960 mg bid
Phase II 150 mg oral dabrafenib twice a day (bid) until disease progression, death, or unacceptable adverse events.
BKM120 Combined with Vemurafenib (PLX4032): Phase I is 3+3 dose escalation study to identify the recommended phase 2 dose (RP2D)</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary Outcome 6 Phase 2 - MAPK Pathway Gene Expression Levels</title>
          <description>Responding tumors lack gene expression signatures of MAPK pathway activation, and progressing tumors demonstrate gene expression signatures of MAPK pathway activation - determined by laboratory tests and tumor assessments.</description>
          <population>Data not collected: study was terminated early due to dose limiting toxicities.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Vemurafenib-Naïve</title>
          <description>150 mg oral dabrafenib twice a day (bid) until disease progression, death, or unacceptable adverse events.
Dose Level -1:
BKM120 60 mg daily Vemurafenib 480 mg bid
Phase I, Dose Level 1:
BKM120 60 mg daily Vemurafenib 720 mg bid
Phase I, Dose Level 2:
BKM120 80 mg daily Vemurafenib 720 mg bid
Phase I, Dose Level 3:
BKM120 100 mg daily Vemurafenib 720 mg bid Phase I, Dose Level 4 BKM120 100 mg daily Vemurafenib 960 mg bid Phase II 150 mg oral dabrafenib twice a day (bid) until disease progression, death, or unacceptable adverse events.
BKM120 Combined with Vemurafenib (PLX4032): Phase I is 3+3 dose escalation study to identify the recommended phase 2 dose (RP2D)</description>
        </group>
        <group group_id="E2">
          <title>Vemurafenib-Resistant</title>
          <description>150 mg oral dabrafenib twice a day (bid) until disease progression, death, or unacceptable adverse events.
Dose Level -1:
BKM120 60 mg daily Vemurafenib 480 mg bid
Phase I, Dose Level 1:
BKM120 60 mg daily Vemurafenib 720 mg bid
Phase I, Dose Level 2:
BKM120 80 mg daily Vemurafenib 720 mg bid
Phase I, Dose Level 3:
BKM120 100 mg daily Vemurafenib 720 mg bid Phase I, Dose Level 4 BKM120 100 mg daily Vemurafenib 960 mg bid Phase II 150 mg oral dabrafenib twice a day (bid) until disease progression, death, or unacceptable adverse events.
BKM120 Combined with Vemurafenib (PLX4032): Phase I is 3+3 dose escalation study to identify the recommended phase 2 dose (RP2D)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Renal insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary Fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>elevated LDH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>high eosinophil count</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>LDH increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>low hematocrit</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>adrenal insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>eye redness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Oral Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hypothermia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Decreased activity level</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Rash on lower abdomen</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>MRSA infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>weight loss</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>QtC Prolongation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>ALT increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>AST increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Decreased wbc</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>anorexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>myalgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>shoulder pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Generalized muscle weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Joint pain (pain in extremity)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>fingertip numbness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Tingling Extremities (Parasthesia)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>somnolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>tremor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Decreased concentration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Groin/testicular pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Rhinnorhea (Pharyngeal mucositis)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash maculopapular</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>photosensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>alopecia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>desquamation of hands &amp; feet</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Dry Skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Crust on elbow</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Erythemia nodosum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study was terminated early due to dose limiting toxicities.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Alain Algazi</name_or_title>
      <organization>University of California, San Francisco</organization>
      <phone>(415) 353-7552</phone>
      <email>alain.algazi@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

